Imidazoline binding sites mediates anticompulsive-like effect of agmatine in marble-burying behavior in mice

European Journal of Pharmacology

Volumn 732, Issue 1, 2014, Pages 26-31

  Dixit, Madhura P ^a   Thakre, Prajwal P ^a   Pannase, Akshay S ^a   Aglawe, Manish M ^a   Taksande, Brijesh G ^a   Kotagale, Nandkishor R ^a  

^a New Kamptee   (India)

Author keywords

Agmatine; Imidazoline binding sites; Marble burying behavior; Obsessive compulsive disorder

Indexed keywords

2 (2 BENZOFURANYL) 2 IMIDAZOLINE; AGMATINE; CLONIDINE; IMIDAZOLINE; MOXONIDINE; UNCLASSIFIED DRUG; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; IMIDAZOLINE DERIVATIVE; IMIDAZOLINE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG BINDING SITE; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; LOCOMOTION; MALE; MOUSE; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; PRIORITY JOURNAL; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; COMPULSIVE BEHAVIOR; DOSE RESPONSE; DRUG EFFECTS; MOTOR ACTIVITY; PSYCHOLOGY;

ADRENERGIC ALPHA-AGONISTS; AGMATINE; ANIMALS; COMPULSIVE BEHAVIOR; DOSE-RESPONSE RELATIONSHIP, DRUG; IMIDAZOLINE RECEPTORS; IMIDAZOLINES; MALE; MICE; MOTOR ACTIVITY;

EID: 84897363103     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2014.02.045     Document Type: Article

References (64)

1. 2-imidazoline receptors in the brain and liver Ann. N. Y. Acad. Sci. 763 1995 506 509
2. 2B-imidazoline receptors by [3H]2-(2-benzofuranyl)-2-imidazoline (2-BFI) in rat brain and liver: characterization, regulation and relation to monoamine oxidase enzymes Naunyn Schmiedebergs Arch. Pharmacol. 356 1997 39 47 (Pubitemid 27276150)
3. A.K. Bence, D.R. Worthen, J.P. Stables, and P.A. Crooks An in vivo evaluation of the antiseizure activity and acute neurotoxicity of agmatine Behav. Brain Res. 74 2003 771 775 (Pubitemid 36126556)
4. J. Budni, V.M. Gadotti, M.P. Kaster, A.R. Santos, and A.L. Rodrigues Role of different types of potassium channels in the antidepressant-like effect of agmatine in the mouse forced swimming test Eur. J. Pharmacol. 575 2007 87 93 (Pubitemid 47576077)
5. 2-site ligands BU 224 and 2-BFI inhibit MAO-A and MAO-B activities, hydrogen peroxide production and lipolysis in rodent and human adipocytes Eur. J. Pharmacol. 552 2006 20 30 (Pubitemid 44754973)
6. P. Bousquet, V. Bruban, S. Schann, and J. Feldman Imidazoline receptors: a challenge Pharm. Acta Helv. 74 2000 205 209 (Pubitemid 30182571)
7. S.F. De Boer, and J.M. Koolhaas Defensive burying in rodents: ethology, neurobiology and psychopharmacology Eur. J. Pharmacol. 463 2003 145 161 (Pubitemid 36205077)
8. H. De Vos, G. Bricca, J. De Keyser, J.P. De Backer, P. Bousquet, and G. Vauquelin Imidazoline receptors, non-adrenergic idazoxan binding sites and alpha 2-adrenoceptors in the human central nervous system Neuroscience 59 1994 589 598
9. D.R. Demady, S. Jianmongkol, and J.L. Vuletich Agmatine enhances the NADP -H oxidase activity of neuronal NO synthase and leads to oxidative inactivation of the enzyme Mol. Pharmacol. 59 2001 24 29 (Pubitemid 32043081)
10. D. Denys Pharmacotherapy of obsessive-compulsive disorder and obsessive-compulsive spectrum disorders Psychiatr. Clin. N. Am. 29 2006 553 584
11. R.M. Eglen, A.L. Hudson, D.A. Kendall, D.J. Nutt, N.G. Morgan, and V.G. Wilson 'Seeing through a glass darkly': casting light on imidazoline 'I' sites Trends Pharmacol. Sci. 19 1998 381 390 (Pubitemid 28458836)
12. D. Farzin, and N. Mansouri Antidepressant-like effect of harmane and other beta-carbolines in the mouse forced swim test Eur. Neuropsychopharmacol. 16 2006 324 328 (Pubitemid 43898669)
13. 2 receptor selective ligand BU224 in naive rats and rats exposed to the stress of the forced swim test Psychopharmacology (Berl) 167 2003 195 202 (Pubitemid 36628162)
14. E. Galea, S. Regunathan, and V. Eliopoulos Inhibition of mammalian nitric oxide synthases by agmatine, an endogenous polyamine formed by decarbo-xylation of arginine J. Biochem. 316 1996 247 249
15. J.A. García-Sevilla, P.V. Escribá, X. Busquets, C. Walzer, and J. Guimón Platelet imidazoline receptors and regulatory G proteins in patients with major depression Neuroreport 8 1996 169 172 (Pubitemid 126785552)
16. Z.H. Gong, Y.F. Li, N. Zhao, H.J. Yang, R.B. Su, and Z.P. Luo Anxiolytic effect of agmatine in rats and mice Eur. J. Pharmacol. 550 2006 112 116 (Pubitemid 44572272)
17. A. Halaris, and J.E. Piletz Imidazoline receptors: possible involvement in the pathophysiology and treatment of depression Hum. Psychopharmacol. 16 2001 65 69
18. A. Halaris, and J.E. Piletz Agmatine metabolic pathway and spectrum of activity in brain CNS Drugs 21 2007 885 900 (Pubitemid 47557104)
19. A. Halaris, H. Zhu, J. Ali, A. Nasrallah, C.L. De Vane, and J.E. Piletz Down-regulation of platelet imidazoline-1-binding sites after bupropion treatment Int. J. Neuropsychopharmacol. 5 2002 37 46 (Pubitemid 34241065)
20. A. Holt Imidazoline binding sites on receptors and enzymes: emerging targets for novel antidepressant drugs? J. Psychiatry Neurosci. 28 2003 409 414 (Pubitemid 38091171)
21. A. Holt, and G.B. Baker Inhibition of rat brain monoamine oxidase enzymes by fluoxetine and norfluoxetine Naunyn Schmiedebergs Arch. Pharmacol. 354 1996 17 24 (Pubitemid 26228454)
22. Y. Ichimaru, T. Egawa, and A. Sawa 5-HT1A-receptor subtype mediates the effect of fluvoxamine, a selective serotonin reuptake inhibitor, on marble-burying behavior in mice 68 1995 65 70 Jpn. J. Pharmacol. 68 1995 65 70
23. S.T. Kaehler, N. Singewald, C. Sinner, and A. Philippu Nitric oxide modulates the release of serotonin in the rat hypothalamus Brain Res. 835 1999 346 349 (Pubitemid 29343800)
24. N.J. Kalk, D.J. Nutt, and A.R. Lingford-Hughes The role of central noradrenergic dysregulation in anxiety disorders: evidence from clinical studies J. Psychopharmacol. 25 2011 3 16
25. N.R. Kotagale, B.G. Taksande, A.Y. Gahane, R.R. Ugale, and C.T. Chopde Repeated agmatine treatment attenuates nicotine sensitization in mice: modulation by alpha2-adrenoceptors Behav. Brain Res. 213 2 2010 161 174
26. N.R. Kotagale, B.G. Taksande, P.J. Wadhwani, M.W. Palhade, S.M. Mendhi, D.Y. Gawande, P.N. Hadole, and C.T. Chopde Psychopharmacological study of agmatine in behavioral tests of schizophrenia in rodents Pharmacol. Biochem. Behav. 100 2012 398 403
27. N.R. Kotagale, S.H. Shirbhate, P. Shukla, and R.R. Ugale Agmatine attenuates neuropathic pain in sciatic nerve ligated rats: Modulation by hippocampal sigma receptors Eur. J. Pharmacol. 714 2013 424 431
28. M. Krass, K. Runkorg, G. Wegener, and V. Volke Nitric oxide is involved in the regulation of marble-burying behavior Neurosci. Lett. 480 2010 55 58
29. D. Lavinsky, N.S. Arteni, and C.A. Netto Agmatine induces anxiolysis in the elevated plus maze task in adult rats Behav. Brain Res. 141 2003 19 24 (Pubitemid 36382913)
30. G. Li, S. Regunathan, C.J. Barrow, J. Eshragi, R. Cooper, and D.J. Reis Agmatine: an endogenous clonidine-displacing substance in the brain Science 263 1994 966 969 (Pubitemid 24094560)
31. Y.F. Li, Z.H. Gong, J.B. Cao, H.L. Wang, Z.P. Luo, and J. Li Antidepressant-like effect of agmatine and its possible mechanism Eur. J. Pharmacol. 469 2003 81 88 (Pubitemid 36629553)
32. T. Londei, A.M. Valentini, and V.G. Leone Investigative burying by laboratory mice may involve non-functional, compulsive, behaviour Behav. Brain Res. 94 1998 249 254 (Pubitemid 28352825)
33. J. Mukherjee, and Z.Y. Yang Monoamine oxidase A inhibition by fluoxetine: an in vitro and in vivo study Synapse 31 1999 285 289 (Pubitemid 29070289)
34. K. Njunge, and S.L. Handley Evaluation of marble-burying behavior as a model of anxiety Pharmacol. Biochem. Behav. 38 1991 63 67
35. G. Olmos, N. DeGregorio-Rocasolano, M. Paz Regalado, T. Gasull, M. Assumpcio Boronat, R. Trullas, A. Villarroel, and J. Lerma Protection by imidazoline drugs and agmatine of glutamate induced neurotoxicity in cultured cerebellar granule cells through blockade of NMDA receptor Br. J. Pharmacol. 127 1999 1317 1326 (Pubitemid 29358932)
36. A. Onal, Y. Delen, S. Ulker, and N. Soykan Agmatine attenuates neuropathic pain in rats: possible mediation of nitric oxide and noradrenergic activity in the brainstem and cerebellum Life Sci. 73 2004 413 428 (Pubitemid 36577566)
37. K. Otake, D. Ruggiero, S. Regunathan, H. Wang, T. Milner, and D. Reis Regional localization of agmatine in the rat brain: an immunocytochemical study Brain Res. 787 1998 1 14 (Pubitemid 28279794)
38. S. Pallanti, and L. Quercioli Treatment-refractory obsessive-compulsive disorder: methodological issues, operational definitions and therapeutic lines Prog. Neuropsychopharmacol. Biol. Psychiatry 30 2006 400 412
39. 1-imidazoline binding sites are decreased by two dissimilar antidepressant agents in depressed patients J. Psychiatr. Res. 30 1996 169 184 (Pubitemid 26335870)
40. J.E. Piletz, H. Zhu, G. Ordway, C. Stockmeier, G. Dilly, D. Reis, and A. Halaris Imidazoline receptor proteins are decreased in the hippocampus of individuals with major depression Biol. Psychiatry 48 2000 910 919
41. J. Piletz, R. Baker, and A. Halaris Platelet imidazoline receptors as state marker of depressive symptomatology J. Psychiatr. Res. 42 2008 41 49 (Pubitemid 47562437)
42. W. Raasch, S. Regunathan, G. Li, and D.J. Reis Agmatine, the bacterial amine, is widely distributed in mammalian tissues Life Sci. 56 1995 2319 2330
43. W. Raasch, H. Muhle, and P. Dominiak Modulation of MAO activity by imidazoline and guanidine derivatives Ann. N. Y. Acad. Sci. 881 1999 313 331 (Pubitemid 29349523)
44. R. Raddatz, A. Parini, and S.M. Lanier Localization of the imidazoline binding domain on monoamine oxidase B Mol. Pharmacol. 52 1997 549 553 (Pubitemid 27443975)
45. S.A. Rasmussen, and J.L. Eisen The epidemiology and clinical features of obsessive-compulsive disorder Psychiatr. Clin. N. Am. 15 1992 743 758 (Pubitemid 23032171)
46. D.J. Reis, and S. Regunathan Is agmatine a novel neurotransmitter in brain? Trends Pharmacol. Sci. 21 2000 187 193 (Pubitemid 30243201)
47. A. Remaury, R. Raddatz, C. Ordener, S. Savic, J.C. Shih, K. Chen, I. Seif, E. De Maeyer, S.M. Lanier, and A. Parini Analysis of the pharmacological and molecular heterogeneity of I(2)-imidazoline-binding proteins using monoamine oxidase-deficient mouse models Mol. Pharmacol. 58 2000 1085 1090
48. A.R.S. Santos, V.M. Gadotti, G.L. Oliveira, D. Tibola, A.F. Paszcuk, and A. Neto Mechanisms involved in the antinociception caused by agmatine in mice Neuropharmacology 48 2005 1021 1034 (Pubitemid 40602610)
49. Y. Sasson, J. Zohar, M. Chopra, M. Lustig, I. Iancu, and T. Hendler Epidemiology of obsessive-compulsive disorder: a world view J. Clin. Psychiatry 58 1997 7 10 (Pubitemid 27516504)
50. E.A. Schilman, O. Klavir, C. Winter, R. Sohr, and D. Joel The role of the striatum in compulsive behavior in intact and orbitofrontal-cortex-lesioned rats: possible involvement of the serotonergic system Neuropsychopharmacology 35 2010 1026 1039
51. J.C. Smith, and P.S. Whitton Nitric oxide modulates N-methyl-d-aspartate- evoked serotonin release in the raphe nuclei and frontal cortex of the freely moving rat Neurosci. Lett. 291 2000 5 8 (Pubitemid 30658099)
52. H. Szechtman, K. Culver, and D. Eilam Role of dopamine systems in obsessive-compulsive disorder (OCD): implications from a novel psychostimulant-induced animal model Pol. J. Pharmacol. 51 1999 55 61 (Pubitemid 29145995)
53. B.G. Taksande, D.S. Faldu, M.P. Dixit, J.N. Sakaria, M.M. Aglawe, M.J. Umekar, and N.R. Kotagale Agmatine attenuates chronic unpredictable mild stress induced behavioral alteration in mice Eur. J. Pharmacol. 720 2013 115 120
54. B.G. Taksande, N.R. Kotagale, S.J. Tripathi, R.R. Ugale, and C.T. Chopde Antidepressant like effect of selective serotonin reuptake inhibitors involve modulation of imidazoline receptors by agmatine Neuropharmacology 57 2009 415 424
55. B.G. Taksande, N.R. Kotagale, M.R. Patel, G.P. Shelkar, R.R. Ugale, and C.T. Chopde Agmatine, an endogenous imidazoline receptor ligand modulates ethanol anxiolysis and withdrawal anxiety in rats Eur. J. Pharmacol. 637 2010 89 101
56. M. Tanaka, M. Yoshida, H. Emoto, and H. Ishii Noradrenaline systems in the hypothalamus, amygdala and locus coeruleus are involved in the provocation of anxiety: basic studies Eur. J. Pharmacol. 405 2000 397 406
57. G. Venkatasubramanian, N.P. Rao, and R.V. Behere Neuroanatomical, neurochemical, and neurodevelopmental basis of obsessive-compulsive symptoms in schizophrenia Indian J. Psychol. Med. 31 2009 3 10
58. G. Wegener, V. Volke, and R. Rosenberg Endogenous nitric oxide decreases hippocampal levels of serotonin and dopamine in vivo Br. J. Pharmacol. 130 2008 575 580
59. Witkin, J.M., 2008. Animal Models of Obsessive-compulsive Disorder. Curr. Protoc. Neurosci. Chapter 9: Unit 9.30.
60. R. Young, S. Batkai, M. Dukat, and R.A. Glennon TDIQ (5,6,7,8-tetrahydro- 1,3-dioxolo[4,5-g]isoquinoline) exhibits anxiolytic-like activity in a marble-burying assay in mice Pharmacol. Biochem. Behav. 84 2006 62 73 (Pubitemid 43975552)
61. M.P. Zeidan, A.D.E. Zomkowski, A.O. Rosa, A.L.S. Rodrigues, and N.H. Gabilan Evidence for imidazoline receptors involvement in the agmatine antidepressant-like effect in the forced swimming test Eur. J. Pharmacol. 565 2007 125 131 (Pubitemid 46805090)
62. H. Zhu, A. Halaris, S. Madakasira, P. Pazzaglia, N. Goldman, C.L. DeVane, M. Andrew, D. Reis, and J.E. Piletz Effect of bupropion on immunodensity of putative imidazoline receptors on platelets of depressed patients J. Psychiatr. Res. 33 1999 323 333 (Pubitemid 29267635)
63. M.Y. Zhu, W.P. Wang, Z.W. Cai, S. Regunathan, and G. Ordway Exogenous agmatine has neuroprotective effects against restraint-induce structural changes in the rat brain Eur. J. Neurosci. 27 2008 1320 1332 (Pubitemid 351406261)
64. A.D.E. Zomkowski, L. Hammes, J. Lin, J.B. Calixto, A.R.S. Santos, and A.L.S. Rodrigues Agmatine produces antidepressant-like effects in two models of depression in mice Neuroreport 13 2002 387 391 (Pubitemid 34293175)